Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
Can Gamida Succeed On Its Own?
Executive Summary
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
You may also be interested in...
Future Uncertain For Gamida Despite Omisirge Optimism
Gamida Cell's Omisirge made it to the US market at the end of last year but despite a better-than-expected launch, the Israeli group has been forced to explore strategic alternatives to survive.
Finance Watch: Ferring Shutters San Diego R&D Site As Even Money-Making Firms Cut Costs
Restructuring Edition: After reporting record revenue, but lower profits due to rising costs, Ferring has decided to consolidate R&D in Europe. Also, Codiak has filed for Chapter 11 bankruptcy and will sell off its assets, while Exicure, Applied Molecular Transport, Gamida Cell and others revealed new job cuts.
Eagle Lands On COVID-Hit Acacia
Acacia launched two hospital drugs – Barhemsys and Byfavo – in the US during COVID but failed to overcome the physical access limitations caused by the pandemic. Eagle of the US thinks it can tap into a potentially lucrative market and is buying the beleaguered biotech.